A detailed history of State Street Corp transactions in Immunocore Holdings PLC stock. As of the latest transaction made, State Street Corp holds 76,671 shares of IMCR stock, worth $2.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76,671
Previous 46,774 63.92%
Holding current value
$2.42 Million
Previous $1.59 Million 50.54%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.06 - $41.49 $898,703 - $1.24 Million
29,897 Added 63.92%
76,671 $2.39 Million
Q2 2024

Aug 14, 2024

BUY
$33.78 - $63.75 $44,859 - $84,660
1,328 Added 2.92%
46,774 $1.59 Million
Q1 2024

May 15, 2024

BUY
$60.14 - $75.36 $115,468 - $144,691
1,920 Added 4.41%
45,446 $2.95 Million
Q4 2023

Feb 14, 2024

BUY
$42.85 - $69.5 $49,706 - $80,620
1,160 Added 2.74%
43,526 $2.97 Million
Q3 2023

Nov 14, 2023

BUY
$49.5 - $66.6 $74,844 - $100,699
1,512 Added 3.7%
42,366 $2.2 Million
Q2 2023

Aug 14, 2023

BUY
$48.54 - $61.64 $81,935 - $104,048
1,688 Added 4.31%
40,854 $2.45 Million
Q1 2023

May 15, 2023

BUY
$46.12 - $65.71 $135,408 - $192,924
2,936 Added 8.1%
39,166 $1.94 Million
Q4 2022

Feb 14, 2023

BUY
$45.51 - $65.08 $1.24 Million - $1.78 Million
27,279 Added 304.76%
36,230 $2.07 Million
Q3 2022

Nov 15, 2022

SELL
$37.34 - $57.44 $107,651 - $165,599
-2,883 Reduced 24.36%
8,951 $420,000
Q2 2022

Aug 15, 2022

BUY
$25.46 - $37.72 $301,293 - $446,378
11,834 New
11,834 $442,000
Q1 2022

May 16, 2022

SELL
$18.94 - $34.29 $119,625 - $216,575
-6,316 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$27.58 - $40.0 $3,199 - $4,640
116 Added 1.87%
6,316 $216,000
Q3 2021

Nov 15, 2021

BUY
$27.98 - $40.0 $173,476 - $248,000
6,200 New
6,200 $230,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.39B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.